GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Price-to-Free-Cash-Flow

Antares Pharma (Antares Pharma) Price-to-Free-Cash-Flow : 93.17 (As of May. 07, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Price-to-Free-Cash-Flow?

As of today (2024-05-07), Antares Pharma's share price is $5.59. Antares Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $0.06. Hence, Antares Pharma's Price-to-Free-Cash-Flow Ratio for today is 93.17.

The historical rank and industry rank for Antares Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

ATRS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 25.38   Med: 94.75   Max: 302.67
Current: 93.17

During the past 13 years, Antares Pharma's highest Price-to-Free-Cash-Flow Ratio was 302.67. The lowest was 25.38. And the median was 94.75.

ATRS's Price-to-Free-Cash-Flow is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 33.98 vs ATRS: 93.17

Antares Pharma's Free Cash Flow per Share for the three months ended in Mar. 2022 was $-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.06.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Antares Pharma was 300.00% per year.

During the past 13 years, Antares Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 47.20% per year. The lowest was -111.20% per year. And the median was 16.10% per year.


Antares Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Antares Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Price-to-Free-Cash-Flow Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 102.31 38.39

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 274.00 128.24 28.00 38.39 68.33

Competitive Comparison of Antares Pharma's Price-to-Free-Cash-Flow

For the Medical Instruments & Supplies subindustry, Antares Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Price-to-Free-Cash-Flow falls into.



Antares Pharma Price-to-Free-Cash-Flow Calculation

Antares Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=5.59/0.06
=93.17

Antares Pharma's Share Price of today is $5.59.
Antares Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Antares Pharma  (NAS:ATRS) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Antares Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447